Tag: cancer stem cells

Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs)

This 2017 study presents a synthetic lethal strategy combining Doxycycline and Vitamin C to eradicate cancer stem cells (CSCs). Doxycycline inhibits mitochondrial protein translation, suppressing mitochondrial DNA-encoded proteins and forcing CSCs into a glycolytic state. This metabolic inflexibility makes them susceptible to Vitamin C, which inhibits glycolysis by targeting GAPDH

Read More »

Role of Vitamin C in Targeting Cancer Stem Cells and Cellular Plasticity

This 2023 review explores the therapeutic potential of vitamin C in targeting cancer stem cells (CSCs) and modulating cellular plasticity. It outlines vitamin C’s dose-dependent dual action: at high pharmacological doses, it acts as a pro-oxidant, generating reactive oxygen species (ROS) that selectively induce apoptosis in cancer cells; at physiological

Read More »

Salinomycin: A new paradigm in cancer therapy

This comprehensive review discusses salinomycin, a polyether antibiotic identified as a potent agent against cancer stem cells (CSCs) and multidrug-resistant tumors. Salinomycin functions by disrupting key oncogenic signaling pathways including Wnt/β-catenin, Notch, Hedgehog, and Akt, reducing CSC viability and enhancing sensitivity to standard chemotherapeutics. Mechanistically, it induces apoptosis, autophagy, and

Read More »

The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug

This 2018 review explores the repositioning of ivermectin, traditionally an antiparasitic agent, as a novel anticancer drug. The article highlights ivermectin’s ability to target multiple molecular pathways critical to cancer cell survival and proliferation. Mechanistically, ivermectin inhibits P-glycoprotein to overcome drug resistance, acts on chloride ion channels to induce apoptosis,

Read More »

Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies

This 2019 review highlights the pivotal role of mitochondria in sustaining cancer stem cells (CSCs), focusing on their metabolic adaptability, regulation of apoptosis, and maintenance of stemness traits that contribute to tumor aggressiveness and therapy resistance. The article examines the rationale for targeting mitochondrial function as a therapeutic strategy, with

Read More »

Epigallocatechin gallate hinders human hepatoma and colon cancer sphere formation

This 2016 study evaluates the inhibitory effects of epigallocatechin gallate (EGCG), a green tea polyphenol, on cancer stem-like cell (CSC) populations derived from human hepatoma and colon cancer cell lines. CSCs were enriched via sphere formation under nonadherent, serum-free conditions and exhibited higher expression of stemness markers, Nek2, and ATP-binding

Read More »

Essential role of the cancer stem/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells

This 2014 study explores the requirement of nucleostemin (NS), a stem/progenitor cell marker, in mediating the anti-proliferative action of indole-3-carbinol (I3C) in human breast cancer cells, particularly HER2-overexpressing 10AT-Her2 cells. These cells exhibit cancer stem cell-like traits (CD44+/CD24−/low and high ALDH-1 activity). Treatment with I3C significantly inhibited tumorsphere formation and

Read More »

Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin

This 2018 review examines several adjunct therapies for pancreatic cancer that have shown promise in preclinical models and retrospective studies. Paricalcitol, a vitamin D analog, disrupts the tumor stroma, enhancing drug delivery. Hydroxychloroquine inhibits autophagy, a survival mechanism in cancer cells. Intravenous vitamin C induces cytotoxic hydrogen peroxide accumulation in

Read More »

Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells

This comprehensive review examines the cancer chemopreventive effects of green tea and its primary catechin, (-)-epigallocatechin gallate (EGCG), based on over three decades of research. The first section highlights key findings, including: Delayed Cancer Onset: A 10-year prospective cohort study indicated that women consuming over 10 cups of green tea

Read More »